5 results about "Co-receptor" patented technology

Soluble gp120 (sgp120) is associated to HIV-1-induced immune dysfunction, such as chronic immune activation. However, the detection of sgp120 in biological fluids such as plasma, serum, cervicovaginal fluids, and cerebrospinal fluids is challenging. The present application relates to novel methods and kits for the detection of sgp120 in biological fluids. These methods and kits are based on the use of specific combinations of sgp120-binding molecules recognizing particular domains of sgp120, notably the N-terminal 8-stranded β-sandwich structure, the constant region 1 and 2 (C1-C2) portion, the bridging sheet of the Co-Receptor Binding Site (CoRBS), and / or the CD4-binding domain.

The present invention provides a modified T cell or population of modified T cells comprising a heterologous recombinant T cell receptor (TCR) and heterologous recombinant co-receptor, additionally provided are methods of producing the modified T cell or population of modified T cells and their use in the treatment of cancer.

The invention provides a method for in-vitro amplification culture of cells. The method comprises the following steps: carrying out pre-culture treatment on the cells, carrying out transfection treatment on the cells by adopting miRNA of a miR-302 family on the 10th-18th day of the pre-culture treatment, and carrying out culture treatment on the transfected cells. Therefore, in a key window period of cell in-vitro culture, miRNA of the miR-302 family is adopted to carry out transfection treatment on the cells, so that the in-vitro amplification capacity of the cells can be effectively improved, meanwhile, the cells can be promoted to express and activate related auxiliary receptors, the killing activity of the cells can be enhanced, and the expression level of chemokine receptors can be improved.

The invention belongs to the field of biochemistry. In particular to an HIV-1 envelope protein open conformation stabilizer and application thereof. More specifically, the invention relates to an HIV-1 envelope protein open conformation stabilizer and its use as a vaccine. The invention provides an HIV-1 envelope protein open conformation stabilizer. The HIV-1 envelope protein open conformation stabilizer comprises at least two of the following proteins: CD4, DC-SIGN and a fusion protein of the CD4 and the DC-SIGN. By using the HIV-1 envelope protein open conformation stabilizer disclosed by the invention, antigen epitopes of a V1V2 section, an auxiliary receptor binding region and the like of the HIV-1 envelope protein can be exposed, and the exposure of the epitopes can better induce the generation of an antibody with a better effect, so that the HIV-1 envelope protein open conformation stabilizer is more beneficial to the prevention and treatment of HIV-1 viruses.

Provided is a genetically engineered cell expressing a co-receptor and a membrane-bound cytokine. The co-receptor comprises a KIR extracellular domain, a transmembrane region, and an intracellular region. When the co-receptor and the membrane-bound cytokine are co-expressed in an immune cell, they can further enhance the cytokine secretion level, proliferation level, and cytotoxicity of the immune cell toward a target cell.